Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b

In melanoma, the adaptative cell response to BRAF inhibitors includes altered patterns of cytokine production contributing to tumor progression and drug resistance. Among the factors produced by PLX4032-resistant melanoma cell lines, CCL2 was higher compared to the sensitive parental cell lines and...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergani, Elisabetta, Di Guardo, Lorenza, Dugo, Matteo, Rigoletto, Sara, Tragni, Gabrina, Ruggeri, Roberta, Perrone, Federica, Tamborini, Elena, Gloghini, Annunziata, Arienti, Flavio, Vergani, Barbara, Deho, Paola, De Cecco, Loris, Vallacchi, Viviana, Frati, Paola, Shahaj, Eriomina, Villa, Antonello, Santinami, Mario, De Braud, Filippo, Rivoltini, Licia, Rodolfo, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826216/
https://www.ncbi.nlm.nih.gov/pubmed/26684239
http://dx.doi.org/10.18632/oncotarget.6599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826216/
https://www.ncbi.nlm.nih.gov/pubmed/26684239
http://dx.doi.org/10.18632/oncotarget.6599

Ejemplares similares